期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雄激素受体在乳腺基底细胞样癌中的表达及意义 被引量：2

Expression of androgen receptor in basal like breast carcinoma and its significance
下载PDF
导出
摘要 目的探讨雄激素受体在乳腺基底细胞样癌(BLBC)中的表达及意义。方法应用组织芯片及免疫组化SP法检测雄激素受体(AR)、雌激素受体(ER)、孕激素受体(PR)及HER2的表达,并结合预后相关因素进行统计学分析。结果AR的阴性表达率为71.07%(86/121),其阴性表达与年龄>50岁、肿瘤高级别、直径>2 cm、淋巴结转移、ER和PR阴性明显相关(P<0.05)。AR的阳性表达率为11.57%(14/121),这些病例呈AR+/ER-/PR-。结论激素受体的阴性表达提示BLBC患者的预后较差。部分病例AR的阳性表达可能有助于探索对ER、PR阴性的BLBC患者实施新的治疗方案。 Purpose To investigate the expression of androgen receptor in basal like breast carcinoma and to explore its significance. Methods Expression of AR, ER, PR and HER2 was detected by S-P immunohistochemical staining using tissue microarray. The relationship with the prognostic factors was analyzed. Results 71.07% BLBC showed negative staining for AR. AR negativity showed a significant relation to age of older than 50 years old, high histological grades, size of lager than 1.5 cm, matastasis of lymph nodes and negative expression of ER and PR （ P 〈 0.05）. 11.57 % （ 14/121 ） cases showed positive expression of AR and negative expression of ER and PR. Conclusion The negative immunostaining of hormone receptor indicates a worse prognosis. The positive expression of AR may be useful to explore new therapeutic strategies for ER and PR negative BLBC patients.
作者 曲桂梅 郎志强 姚卫东 于国华 封小丽
机构地区 烟台市毓璜顶医院病理科
出处 《诊断病理学杂志》 CSCD 2008年第6期485-487,共3页 Chinese Journal of Diagnostic Pathology
关键词 雄激素受体 乳腺基底细胞样癌 组织芯片 Androgen receptor Basal like breast carcinoma Tissue microarray
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1杨光之,皋岚湘,丁华野.乳腺基底细胞样癌[J].诊断病理学杂志,2007,14(4):241-244. 被引量：24
  • 2Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [ J ]. Mod Pathol, 2006, 19(2):264-271.
  • 3Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10(16) :5367 - 5374.
  • 4Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression [ J ]. Histopathology, 2007, 50 (4) : 434 - 438.
  • 5皋岚湘,杨光之,丁华野,李琳.基底细胞样型浸润性乳腺癌病理形态观察[J].中华病理学杂志,2008,37(2):83-87. 被引量：36
  • 6Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen [ J ]. Oncogene, 2006, 25(28) :3994 -4008.
  • 7Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negetive breast cancer[J]. Cancer, 2007, 109(1):25- 32.
  • 8Gonzalez LO, Corte MD, Junquera S, et al. Expression of androgen receptor and two androgen-induced proteins (apohpoprotein D and pepsinogen C ) in ductal carcinoma in situ of the breast [ J ]. Histopathology, 2007, 50(7) :866 - 874.
  • 9Cox DG, Blanche H, Pearce CL, et al. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)[J]. Breast Cancer Res, 2006, 8(5): R54.
  • 10Anim JT, John B, Abdulsathar SSA, et al. Relationship between the expression of various markers and prognostic factors in breast cancer [J]. Acta Histochem, 2005, 107(2) :87 - 93.

二级参考文献46

  • 1步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量：24
  • 2Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin : three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch, 2005, 447(4):688-694.
  • 3Finak G, Sadekova S, Pepin F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res, 2006, 8(5) :R58.
  • 4Perou CM, Sφrlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797) :747-752.
  • 5Sφrlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nail Aead Sci U S A, 2001, 98(19) :10869-10874.
  • 6Sφrlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Nail Acad Sci U S A, 2003, 100(14):8418-8423.
  • 7Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A, 2003,100(18):10393-10398.
  • 8Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10(16) :5367-5374.
  • 9Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology, 2006,49(1):22-34.
  • 10Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology, 2006, 49(1):10-21.

共引文献55

同被引文献22

  • 1Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of hu- man breast tumors [ J ]. Nature, 2000, 406 (6797) :747 - 52.
  • 2Agoff S N, Swanson P E, Linden H, et al. Androgen receptor ex- pression in estrogen receptor-negative breast cancer: immunohisto- chemical, clinical, and prognostic associations [ J ]. Am J Clin Pathol, 2003,120(5) :725 -31.
  • 3Hammond M E, Hayes D F, Dowsett M, et al. American society of clinical oncology/college of american pathologists guideline rec- ommendations for immunohistochemical testing of estrogen and pro- gesterone receptors in breast cancer [ J]. J Clin Oncol, 2010,28 (16) :2784 -95.
  • 4Wolff A C, Hammond M E, Hicks D G, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast canc- er: american society of clinical oncology/college of american pa- thologists clinical practice guideline update [ J ]. Arch Pathol LabMed, 2014,138(2) :241 -56.
  • 5Nielsen T O, Hsu F D, Jensen K, et al. Immunohistochemical and clinical characterization of thebasallike subtype of imvasive breast cancer[ J]. Clin Cancer Res, 2004,10(16) :5367 - 74.
  • 6Park S, Koo J, Park H S, et al. Expression of androgen receptors in primary breast cancer[ J ]. Ann Oncol, 2010,21 ( 3 ) :488 - 92.
  • 7Nahleh Z. Androgen receptor as a target for the treatment of hor- mone receptor-negative breast cancer: an unchartered territory [ J ]. Future Oncol, 2008,4 ( 1 ) : 15 - 21.
  • 8Eriko T, Yuichi H, Kenji T, et al. Differential impact of the ex- pression of the androgen receptor by age in estrogen receptor - positive breast cancer [ J ]. Cancer Med, 2013,2 ( 6 ) :763 - 73.
  • 9Hankinson S E, Willett W C, Manson J E, et al. Plasma sex ster- oid hormone levels and risk of breast cancer in postmenopausal women[J]. J Natl Cancer Inst, 1998,90(17) :1292 -9.
  • 10Dorgan J F, Longcope C, Stephenson H E Jr, et al. Relation of prediagnostic serum estrogen and androgen leves to breast cancer risk[ J]. Cancer Epidemiol Biomarkers Prey, 1996, 5 (7) :533 - 9.

引证文献2

二级引证文献8

诊断病理学杂志
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部